Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 10, 2023 (Event Date)
Reporting Period: Specific event reporting; not a periodic financial report.
Key Financial Metrics
This filing reports a specific commercial agreement rather than periodic financial performance. Consequently, standard metrics such as revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
- Upfront Payment: $12 million to be received from Nippon Shinyaku, Co., Ltd.
- Potential Milestone Payments: Up to approximately $89 million (development and sales-based).
- Revenue Share: Meaningful, double-digit share of product revenue.
Material Changes
The primary material change is the entry into an Exclusive Commercialization and Distribution Agreement with Nippon Shinyaku, Co., Ltd., effective February 10, 2023.
- Product: CAP-1002, the Company's lead product candidate for the treatment of Duchenne muscular dystrophy.
- Territory: Japan.
- Roles: Nippon Shinyaku serves as the exclusive distributor. Capricor retains responsibility for clinical development in Japan, manufacturing, and holding the Marketing Authorization.
Guidance, Outlook, and Risks
Outlook: The agreement establishes a pathway for commercialization in Japan, contingent upon regulatory approval and successful clinical development.
Risks and Contingencies:
- Regulatory Approval: Capricor must obtain Marketing Authorization in Japan for the product to be distributed.
- Development Risk: Capricor remains responsible for conducting clinical development in Japan as required.
- Confidentiality: Certain terms of the agreement are subject to confidential treatment and will be filed as an exhibit to the Form 10-K for the year ended December 31, 2022.
Investor Verification Checklist
- Verify the receipt of the $12 million upfront payment in subsequent financial filings.
- Review the full text of the Japan Agreement when filed as an exhibit to the Form 10-K for specific milestone triggers and royalty rates.
- Monitor clinical trial progress for CAP-1002 in Japan to assess the likelihood of achieving milestone payments.
- Confirm the status of Marketing Authorization applications with Japanese regulatory bodies.